
**A 2-years post-doctoral position funded by INCa (Institut National du Cancer)
is available at MEDyC research unit in Reims (France)
- UMR CNRS 7369, “Extracellular matrix, Cancer and Therapeutic target” team -**

This INCa-funded project is based on a unique academic-industry R&D partnership gathering together MEDyC unit (CNRS UMR7369), Gustave Roussy Institute and Apmonia Therapeutics, a biotech company dedicated to developing anti-cancer immunotherapy strategies.

The goal of the project is to deeply **investigate the relevance of targeting the TSP-1/CD47 axis in the purpose of restoring anti-tumor immunity in ovarian cancer**, one of the highest unmet medical needs in oncology. We will seek to open new therapeutic perspectives for the treatment of ovarian cancer focusing our attention on an **optimized drug candidate (TAX2)** with highly advanced preclinical characterization.

As a priority, the post-doctoral research scientist will further decipher and characterize the TAX2-mediated immune response (*in vitro* & *in vivo*) to strengthen the proof-of-mechanism for TAX2-related immunomodulation in ovarian cancer. He/She will also contribute to provide a rationale for an optimized therapeutic combination strategy using TAX2 drug candidate.

We are therefore looking for a highly motivated candidate with **significant background in onco-immunology** (knowledge and technical skills) and **mouse tumor models** (animal experimentation degree is an essential prerequisite).

Ideally, the candidate would have several years of research in the field of **tumor microenvironment** with expertise on extracellular matrix components.

The candidate will have to work in close interaction with the two other partners of the project, namely Gustave Roussy Institute and Apmonia Therapeutics R&D team. Organization skills, strength of proposal, team spirit and high level of autonomy are required.

Interested candidates are invited to send a detailed CV with publication list, motivation letter and referees names to Pr. Stéphane Dedieu (stephane.dedieu@univ-reims.fr)

Key words: tumor microenvironment, extracellular matrix, immuno-oncology, ovarian cancer, therapeutic combinations.